Displaying 1 - 5 of 5 results.
Breast Implant Associated - Anaplastic Large-Cell Lymphoma (BIA - ALCL)
Breast Implant Associated - Anaplastic Large-Cell Lymphoma (BIA - ALCL),
HPRA Website, - Anaplastic Large-Cell Lymphoma (BIA – ALCL) Last Updated: 30 August 2019 Background BIA-ALCL, ) provisional recognition as a type of ALCL in 2016. It can be difficult to accurately explain the risk of developing rare conditions such as BIA-ALCL, but it is important that individuals, BIA-ALCL has been shown to be more common than first thought, but it still remains a rare condition
Breast Implants
-ALCL) and ‘Breast Implant Illness’. BIA-ALCL is a rare but important condition that has been, can also be submitted to the HPRA by post. The HPRA has specific advice in relation to BIA-ALCL, - Anaplastic Large-Cell Lymphoma (BIA – ALCL) Some individuals who have breast implants may experience, , and the healthcare professionals who look after them, are aware that ‘Breast implant illness’ and BIA-ALCL, of breast implant safety and conditions such as BIA-ALCL increases, the HPRA would like to reiterate
Allergan Textured Breast Implants
; Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). European and International, between breast implants and this rare lymphoma. Although most cases of BIA-ALCL reported worldwide, the surface texture of implants and BIA-ALCL has not been established and the mechanism for the development of BIA-ALCL is yet to be determined. The HPRA is continuing to closely monitor and assess the issue of BIA-ALCL. For more information on BIA-ALCL, see the dedicated section of the HPRA Website
Displaying 1 - 2 of 2 results.
MODRASONE
Active Substance(s): ALCLOMETASONE DIPROPIONATE
Strength & Dosage: 0.05 %w/w Cream
PA1619/005/001
Authorised: 13/08/1984
Aspire Pharma Limited
MODRASONE
Active Substance(s): ALCLOMETASONE DIPROPIONATE
Strength & Dosage: 0.05 %w/w Ointment
PA1619/005/002
Authorised: 13/08/1984
Aspire Pharma Limited